#Denosumab #Mabwell #ANVISA

Mabwell's Latest Achievement: Securing Brazilian GMP Certification

Mabwell, a prominent biopharmaceutical company based in Shanghai, has recently made headlines by successfully passing the Brazilian Health Regulatory Agency's (ANVISA) Good Manufacturing Practice (GMP) inspection. This milestone not only marks a significant achievement for the firm but also highlights its commitment to maintaining high-quality standards in the production of biopharmaceuticals, specifically its denosumab biosimilars, 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar).

A Growing Footprint in the Pharmaceutical Market

Brazil, being the largest economy in Latin America and a vital member of the BRICS nations, holds the region's largest pharmaceutical market. The rigorous standards upheld by ANVISA, a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), are well-aligned with international rules set by both the International Council for Harmonisation (ICH) and the World Health Organization (WHO). Consequently, passing the ANVISA GMP inspection signals a robust endorsement of Mabwell's quality management systems.

This accomplishment is not Mabwell's first entry into international markets. The company had previously garnered market authorization for its denosumab biosimilars in eight different countries, including Brazil, further underlining its global outreach and ambition. Additionally, the firm has succeeded in obtaining marketing approval in Pakistan, thus expanding its global footprint in the biopharmaceutical landscape.

Commitment to Quality and Accessibility

Mabwell's mission revolves around addressing significant medical needs by providing more effective and accessible therapies, particularly in the fields of oncology and age-related diseases. Their vision,